Helixgate

Helixgate

Uncategorized

UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B

The acquisition helps diversify UCB’s small molecule-centric arsenal of seizure treatments with a potentially one-off therapy in early testing for a hard-to-treat form of a common epilepsy.

Read More

Published

on

The acquisition helps diversify UCB’s small molecule-centric arsenal of seizure treatments with a potentially one-off therapy in early testing for a hard-to-treat form of a common epilepsy.

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Optimism for Trump’s CDC pick is tempered by questions about RFK Jr.’s role

The nomination of a new leader for the Centers for Disease Control and Prevention — one who has scientific credentials and no public ties to the anti-vaccine movement — has generated sighs of relief in the public health world. 

As one CDC employee, who asked not to be named, put it on Friday, among staff “the general vibe is guarded but hopeful.”

Read the rest…

Read More

Published

on

The nomination of a new leader for the Centers for Disease Control and Prevention — one who has scientific credentials and no public ties to the anti-vaccine movement — has generated sighs of relief in the public health world. 

As one CDC employee, who asked not to be named, put it on Friday, among staff “the general vibe is guarded but hopeful.”

Read the rest…

Read More

Continue Reading

Uncategorized

RevMed’s stunning success; FDA to reclassify peptides; and more

RevMed’s stunning success; FDA to reclassify peptides; and more

Published

on

Welcome back to Endpoints Weekly! Q1 earnings season is officially upon us. Max Gelman kicked off our coverage this week with a story about Johnson & Johnson’s confidence in navigating biosimilar competition …​ ​Read More

Continue Reading

Uncategorized

AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’

Asked by Fierce if he’d consider returning to the FDA, Pazdur said he wouldn’t serve again under the Trump administration “for obvious reasons.”​Read More

Published

on

Asked by Fierce if he’d consider returning to the FDA, Pazdur said he wouldn’t serve again under the Trump administration “for obvious reasons.”​Read More

Continue Reading
Advertisement

Trending